Xeris制药 2024年度报告

(Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31, 2024orTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _______ to _______Commission file number: 001-40880XERIS BIOPHARMA HOLDINGS, INC. (Exact name of the registrant as specified in its charter) (844) 445-5704 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined by Rule 405 of the Securities Act.Yes’Noh Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.Yes’Noh Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past90 days.Yes hNo’ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).YeshNo’ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerginggrowth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 ofthe Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.j Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control overfinancial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.h If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect thecorrection of an error to previously issued financial statements.j Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of theregistrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).j As of June 30, 2024, the aggregate market value of the Registrant's common stock held by non-affiliates of the Registrant was approximately $335.1 million based onthe closing sales price as reported on the Nasdaq Stock Market. As of February 28, 2025, 153,940,135 shares, par value $0.0001 per share, of common stock were outstanding. DOCUMENTS INCORPORATED BY REFERENCE Part III incorporates certain information by reference from the Registrant's Definitive Proxy Statement to be filed with the Commission in connection with theRegistrant's 2025 Annual Meeting of Stockholders. Such Definitive Proxy Statement will be filed not later than 120 days after the conclusion of the Registrant’s fiscalyear ended December 31, 2024. Summary of the Material Risks Associated with Our Business Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business. These risksinclude, but are not limited to, the following: ∞We have a limited operating history and limited experience commercializing pharmaceutical products and have incurredsignificant losses since inception.∞We may never be profitable or be able to sustain revenues or, if achieved, sustain profitability in the future and we may notbe able to continue operations without additional fundings.∞We may require additional capital to sustain our business, and this capital may cause dilution to our stockholders and mightnot be available on terms favorable to us, or at all, which could force us to delay, reduce or eliminate our productdevelopment programs or commercialization efforts.∞Our business depends entirely on the commercial success of our products and product candidates. Even if approved, ourproduct candidates may not be accepted in the marketplace and our business may be materially harmed.∞We operate in a competitive business environment, which may have an adverse impact on our revenue. If we are unable tocompete successfully against our existing or future competitors, our sales and operating results may be negatively affectedand we may not successfully commercialize our products or product candidates, even if approved.∞If we are unable to establish or do not maintain sufficient marketin